Evaluation of ex vivo expansion and engraftment in NOD-SCID mice of umbilical cord blood CD34+ cells using the DIDECO 'Pluricell System'

Bone Marrow Transplantation

Volumn 35, Issue 11, 2005, Pages 1101-1106

  Astori, G ^a   Adami, V ^b   Mambrini, Giovanni ^a   Bigi, L ^a   Cilli, M ^c   Facchini, A ^d   Falasca, E ^b   Malangone, W ^b   Panzani, I ^a   Degrassi, A ^e  

^a DIDECO Srl   (Italy)

^b SB Technology   (Italy)

^c UNIVERSITY OF GENOA   (Italy)

^d Laboratorio di Immunologia e Genetica   (Italy)

^e UNIVERSITY OF UDINE   (Italy)

Author keywords

Bioreactors; Disposable equipment; Hematopoietic stem cell transplantation; Umbilical cord blood

Indexed keywords

CD34 ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; B LYMPHOCYTE; BLOOD VOLUME; BONE MARROW CELL; BONE MARROW EXAMINATION; CELL LINEAGE; CELL POPULATION; CELL PROLIFERATION; CELL TRANSPLANTATION; CONTROLLED STUDY; EQUIPMENT DESIGN; ERYTHROID CELL; HEMATOPOIESIS; INOCULATION; MEGAKARYOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANK SUM TEST; SCID MOUSE; STEM CELL; STEM CELL MOBILIZATION; T LYMPHOCYTE; UMBILICAL CORD BLOOD;

ANIMALS; ANTIGENS, CD34; ANTIGENS, CD45; BIOREACTORS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL CULTURE TECHNIQUES; CELL LINEAGE; CELLS, CULTURED; FETAL BLOOD; FLOW CYTOMETRY; HEMATOPOIETIC STEM CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; TIME FACTORS;

EID: 20044395165     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704964     Document Type: Article

References (37)

1. Kurtzberg J, Laughlin M, Graham ML et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N Engl J Med 1996; 335: 157-166.
2. Gluckman E, Rocha V, Arcese W et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32: 397-407.
3. Wagner JE, Verfaillie CM. Ex vivo expansion of umbilical cord blood hemopoietic stem and progenitor cells. Exp Hematol 2004; 32: 412-413.
4. Migliaccio AR, Adamson JW, Stevens CE et al. Cell dose and speed of engraftment in placental/umbilical cord blood transplantation: graft progenitor cell content is a better predictor than nucleated cell quantity. Blood 2000; 96: 2717-2722.
5. Rubinstein P, Carrier C, Scaradavou A et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998; 339: 1565-1577.
6. Gluckman E, Rocha V, Arcese W et al. Factors associated with outcomes of unrelated cord blood transplant: guidelines for donor choice. Exp Hematol 2004; 32: 397-407.
7. Locatelli F, Rocha V, Chastang C et al. Factors associated with outcome after cord blood transplantation in children with acute leukemia. Eurocord-Cord Blood Transplant Group. Blood 1999; 93: 3662-3671.
8. Naparstek E, Hardan Y, Ben-Shahar M et al. Enhanced marrow recovery by short preincubation of marrow allografts with human recombinant interleukin-3 and granulocyte-macrophage colony-stimulating factor. Blood 1992; 80: 1673-1678.
9. Brugger W, Heimfeld S, Berenson RJ et al. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995; 333: 283-287.
10. Williams SF, Lee WJ, Bender JG et al. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood 1996; 87: 1687-1691.
11. Alcorn MJ, Holyoake TL, Richmond L et al. CD34-positive cells isolated from cryopreserved peripheral-blood progenitor cells can be expanded ex vivo and used for transplantation with little or no toxicity. J Clin Oncol 1996; 14: 1839-1847.
12. Reiffers J, Cailliot C, Dazey B et al. Abrogation of post-myeloablative chemotherapy neutropenia by ex-vivo expanded autologous CD34-positive cells. Lancet 1999; 354: 1092-1093.
13. Shpall EJ, Quinones R, Giller R et al. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 2002; 8: 368-376.
14. McNiece I, Jones R, Bearman SI et al. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood 2000; 96: 3001-3007.
15. Paquette RL, Dergham ST, Karpf E et al. Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. Exp Hematol 2002; 30: 374-380.
16. Paquette RL, Dergham ST, Karpf E et al. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood 2000; 96: 2385-2390.
17. Scheding S, Bergmannn M, Rathke G et al. Additional transplantation of ex vivo generated megakaryocytic cells after high-dose chemotherapy. Haematologica 2004; 89: 630-631.
18. Pecora AL, Stiff P, LeMaistre CF et al. A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 295-303.
19. Astori G, Malangone W, Adami V et al. A novel protocol that allows short-term stem cell expansion of both committed and pluripotent hematopoietic progenitor cells suitable for clinical use. Blood Cells Mol Dis 2001; 27: 715-724.
20. Malangone W, Belvedere O, Feruglio C et al. Flow cytometric characterization of ex vivo expanded umbilical cord blood CD34(+) cells. Transplant Proc 2001; 33: 1764-1765.
21. Petzer AL, Zandstra PW, Piret JM, Eaves CJ. Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin. J Exp Med 1996; 183: 2551-2558.
22. Piacibello W, Sanavio F, Garetto L et al. Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood. Blood 1997; 89: 2644-2653.
23. Piacibello W, Sanavio F, Garetto L et al. Differential growth factor requirement of primitive cord blood hematopoietic stem cell for self-renewal and amplification vs proliferation and differentiation. Leukemia 1998; 12: 718-727.
24. Bhatia M, Bonnet D, Kapp U et al. Quantitative analysis reveals expansion of human hematopoietic repopulating cells after short-term ex vivo culture. J Exp Med 1997; 186: 619-624.
25. Kamel-Reid S, Dick JE. Engraftment of immune-deficient mice with human hematopoietic stem cells. Science 1988; 242: 1706-1709.
26. Hogan CJ, Shpall EJ, McNulty O et al. Engraftment and development of human CD34(+)-enriched cells from umbilical cord blood in NOD/LtSz-scid/scid mice. Blood 1997; 90: 85-96.
27. Dick JE. Normal and leukemic human stem cells assayed in SCID mice. Semin Immunol 1996; 8: 197-206.
28. Conneally E, Cashman J, Petzer A, Eaves C. Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice. Proc Natl Acad Sci USA 1997; 94: 9836-9841.
29. Committee for Proprietary Medicinal Products. Points to consider on the manufacture and quality control of human somatic cell therapy medicinal products CPMB/BWP/41450/98. 2004.
30. Qiu L, Meagher R, Welhausen S et al. Ex vivo expansion of CD34+ umbilical cord blood cells in a defined serum-free medium (QBSF-60) with early effect cytokines. J Hematother Stem Cell Res 1999; 8: 609-618.
31. Briddell RA, Kern BP, Zilm KL et al. Purification of CD34+ cells is essential for optimal ex vivo expansion of umbilical cord blood cells. J Hematother 1997; 6: 145-150.
32. Douay L. Experimental culture conditions are critical for ex vivo expansion of hematopoietic cells. J Hematother Stem Cell Res 2001; 10: 341-346.
33. Haylock DN, Horsfall MJ, Dowse TL et al. Increased recruitment of hematopoietic progenitor cells underlies the ex vivo expansion potential of FLT3 ligand. Blood 1997; 90: 2260-2272.
34. Hunnestad JA, Steen R, Tjonnfjord GE, Egeland T. Thrombopoietin combined with early-acting growth factors effectively expands human hematopoietic progenitor cells in vitro. Stem Cells 1999; 17: 31-38.
35. Rossmanith T, Schroder B, Bug G et al. Interleukin 3 improves the ex vivo expansion of primitive human cord blood progenitor cells and maintains the engraftment potential of scid repopulating cells. Stem Cells 2001; 19: 313-320.
36. Rubinstein P, Dobrila L, Rosenfield RE et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995; 92: 10119-10122.
37. Sutherland DR, Anderson L, Keeney M et al. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. International Society of Hematotherapy and Graft Engineering. J Hematother 1996; 5: 213-226.